Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin

Research output: Contribution to journalArticle

Abstract

Aims and background: To assess the activity and tolerability of the combination of mitomycin C and capecitabine in patients with metastatic colorectal cancer after failure of irinotecan-and oxaliplatin-containing regimens. Methods: We retrospectively reviewed 28 patients with pretreated advanced colorectal cancer who had been treated with mitomycin C, 6 mg/m 2 on day 1, and capecitabine, 1,900 mg/m2 on days 1-14, every 3 weeks. Tumor assessment was performed every 3 cycles, toxicity assessed at each cycle. Results: Main patient characteristics were median age, 61 years (range, 35-73); male/female ratio, 16/12; single metastatic site involvement, 5/28 (18%); ≥3 metastatic sites, 10/28 (36%). Ninety-six courses of therapy were given (median number, 3; range, 1-9). Twenty-six patients were assessable for response, and all were assessable for toxicity. There was 1 partial response (4%) and 12 had stable disease (43%). Median time to progression was 2 months (range, 1-9) and median overall survival was 6 months (range, 1-29+), with a 1-year overall survival rate of 25%. The regimen was very well tolerated without significant hematological toxicity. Conclusions: Our results are disappointing. Despite the good safety profile, they do not support further investigation or the routine use of this regimen in this setting.

Original languageEnglish
Pages (from-to)285-289
Number of pages5
JournalTumori
Volume92
Issue number4
Publication statusPublished - Jul 2006

Keywords

  • Advanced colorectal cancer
  • Capecitabine
  • Mitomycin C

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin'. Together they form a unique fingerprint.

  • Cite this